期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

Ⅱ类组蛋白去乙酰化酶与临床

Class Ⅱ members of histone deacetylases and clinic significance
下载PDF
导出
摘要 Ⅱ类组蛋白去乙酰化酶(HDACs)及其相互作用分子在与临床相关的生物学过程中发挥着重要作用。近年来发现,Ⅱ类组蛋白去乙酰化酶与临床心血管疾病、呼吸系统疾病和骨软骨疾病的发生、肿瘤进展以及药学研究等密切相关。本文就Ⅱ类HDACs与临床的关系进行了综述。 Class Ⅱ members of histone deacetylases and their interactional moleculars play an important role in biological processes of clinical relevance.Resent reports revealed that the development of cardiovascular diseases,respiratory system and bone diseases,the progress of the tumor and clinical pharmaceutical research have been directly or indirectly correlated with Class Ⅱ members of HDACs.This review is focused on the relationship between the HDACs and clinical diseases.
作者 王红晖 万玉民 李莹辉
机构地区 中国航天员中心航天医学基础与应用国家重点实验室
出处 《基础医学与临床》 CSCD 北大核心 2011年第1期101-103,共3页 Basic and Clinical Medicine
基金 中国载人航天预先研究项目(2007SY5414007)
关键词 组蛋白 乙酰化修饰 组蛋白去乙酰化酶 临床 histone acetylate modification histone deacetylases clinic
分类号 R341 [医药卫生—基础医学]
  • 相关文献

参考文献1

二级参考文献31

  • 1WILLIAM KK, OWEN OC, LEE KM. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer[J]. J Clin Oncol, 2005, 23 (17) : 3923-3931.
  • 2BLUMENSCHEIN G, LU C, KIES M, et al. Phase Ⅱ clinical trial of suberoylanilide hydroxamic acid(SAHA) in patients with recurrent and/or metastatic head and neck cancer (SCCHN) [J]. J Clin Oncol, 2004, 22 (14 Suppl) : 5578.
  • 3RICHON VM. Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor[J]. Br J Cancer, 2006, 95 Suppl 1 : S2-S6.
  • 4OTTMANN OG, DEANGELO DJ, STONE RM, et al.A phase Ⅰ pharmacokinetic (PK)and pharmacodynamic (PD)study of a novel histone deacetylase inhibitor LAQ824 in patients with hematologic malignancies [J]. J Clin Oncol, 2004, 22 (14 Suppl) : 3024-3028.
  • 5ROWINSKY EK, BONO J, DEANGELO DJ, et al. Cardiac monitoring in phase Ⅰ trials of a novel histone deaeetylase (HDAC) inhibitor LAQ824 in patients with advanced solid tumors and hematologic malignancies[J]. J Clin Oncol, 2005, 23 (16 Suppl) : 3131.
  • 6STEELE NL, PLUMB JA, VIDAL L, et al. A phase 1 pharmacokinetic and pharmacodynamic study of the histone deaeetylase inhibitor belinostat in patients with advanced solid tumors[J]. Clin Cancer Res, 2008, 14(3): 804-810.
  • 7BYRD JC, MARCUCCI G, PARTHUN MR, et al. A phase 1 and pharmacodynamc study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia [J]. Blood, 2005, 105(3) : 959-967.
  • 8SHAH MH, BINKLEY P, CHAN K, et al. Cardiotoxicity of histone deaeetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors[J]. Clin Cancer Res, 2006, 12 (13) : 3997-4003.
  • 9PATNAIK A, ROWINSKY EK, VILLALONA MA, et al. A phase Ⅰ study of pivaloyloxymethyl butyrate a prodrug of the di. erentiating agent butyric acid in patients with advanced solid malignancies[J]. Clin Cancer Res, 2002, 8(7): 2142-2148.
  • 10REID T, VALONE F, LIPERA W, et al. Phase Ⅱ trial of the histone deacetylaseinhibitor pivaloyloxymethyl butyrate (Pivanex AN-9) in advanced non-small cell lung cancer [J]. Lung Can, 2004, 45(3): 381-386.

共引文献3

基础医学与临床
2011年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部